The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). Since its launch more than a decade ago, the landmark public-private partnership has made major contributions to AD research, enabling the sharing of data between researchers around the world.
Three overarching goals of the ADNI study are:
- To detect AD at the earliest possible stage (pre-dementia) and identify ways to track the disease’s progression with biomarkers.
- To support advances in AD intervention, prevention, and treatment through the application of new diagnostic methods at the earliest possible stages (when intervention may be most effective).
- To continually administer ADNI’s innovative data-access policy, which provides all data without embargo to all scientists in the world.
ADNI began in 2004 under the leadership of Dr. Michael W. Weiner, funded as a private-public partnership with $27 million contributed by 20 companies and two foundations through the Foundation for the National Institutes of Health and $40 million from the National Institute on Aging. The initial five-year study (ADNI-1) was extended by two years in 2009 by a Grand Opportunities grant (ADNI-GO), and in 2011 and 2016 by further competitive renewals of the ADNI-1 grant (ADNI-2, and ADNI-3, respectively). Learn more about each phase of the study in the table below.
New participants were recruited across North America during each phase of the study and agreed to complete a variety of imaging and clinical assessments. Participants are followed and reassessed over time to track the pathology of the disease as it progresses. Results are then shared by ADNI through the USC Laboratory of Neuro Imaging’s Image and Data Archive (IDA). Learn more about each phase of the study in the table below.
Whole Genome Sequencing Data
In July 2012, the Brin-Wojcicki Foundation and the Alzheimer’s Association donated funds to support whole genome sequencing (WGS) of 818 ADNI participants (at the time: 128 with AD, 415 with MCI, 267 controls and 8 of uncertain diagnosis). Samples were sent to Illumina, where non-CLIA WGS, as well as Illumina Omni 2.5M genome-wide association study (GWAS) single nucleotide polymorphism (SNP) arrays, were performed on each sample and completed in Spring 2013. Basic quality control checks were then performed and additional checks are continually performed.
Information obtained from the ADNI website on August 28, 2018.
Administrative Core PI
Michael W. Weiner, M.D.
UCSF, NCIRE, VA Medical Center
Genetics Core PI
Andrew J. Saykin, Psy.D.
Visit the ADNI Centers and Cores page for more information.
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U19 AG024904). ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of Southern California. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.
Visit the ADNI website for more information about their funding sources.
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
For investigators using ADNI data:
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Additional information to include in an acknowledgment statement can be found on the LONI site: https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Data_Use_Agreement.pdf.